Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23727436 | 0.90 | LMNA (0.45) | LMNACYP3A4CYP2D6MAPK1THPO | |
| SCHEMBL30125726 | 0.90 | LMNA (0.45) | LMNACYP3A4CYP2D6MAPK1THPO | |
| SCHEMBL12676668 | 0.85 | MEN1 (0.51) | ALDH1A1VDRKMT2AMEN1TAAR1 | |
| SCHEMBL24598179 | 0.83 | THRB (0.42) | LMNACYP3A4CYP2D6MAPK1THPO | |
| SCHEMBL6098372 | 0.82 | ALDH1A1 (0.48) | LMNACYP3A4CYP2D6MAPK1THPO | |
| SCHEMBL8209789 | 0.82 | TP53 (0.51) | LMNAMAPK1ALDH1A1VDRKMT2A | |
| SCHEMBL2568984 | 0.82 | ALDH1A1 (0.48) | LMNAMAPK1ALDH1A1VDRKMT2A | |
| SCHEMBL1904847 | 0.82 | VDR (0.40) | LMNAMAPK1ALDH1A1VDRKMT2A | |
| SCHEMBL28774223 | 0.82 | MEN1 (0.46) | LMNAMAPK1VDRKMT2AMEN1 | |
| SCHEMBL9316876 | 0.81 | CA12 (0.47) | VDRKMT2AMEN1TAAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | PHARMA MAR, S.A.U. (ES) | 2006-12-21 | — | — | US | disclosed |
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| EP-1613635-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004073598-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A.U. (ES) | 2004-09-02 | — | — | WO | disclosed |
| EP-1423356-A2 | NOVEL AMINOBENZOEPHENONES | Leo Pharma A/S (DK) | 2004-06-02 | — | — | EP | disclosed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | disclosed |
| WO-2003018535-A2 | NOVEL AMINOBENZOEPHENONES | LEO PHARMA A/S (DK) | 2003-03-06 | — | — | WO | disclosed |
| EP-1090008-A4 | SYNTHESES OF A VARIETY OF LAMELLARIN COMPOUNDS AND ANALOGUES | UNIV AUSTRALIAN (AU) | 2003-01-02 | — | — | EP | disclosed |
| US-6469171-B1 | NON-TOXIC MODULATORS OF THE MULTIDRUG RESISTANT PHENOTYPE | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2002-10-22 | — | — | US | disclosed |
| EP-1090008-A1 | SYNTHESES OF A VARIETY OF LAMELLARIN COMPOUNDS AND ANALOGUES | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067250-A1 | SYNTHESES OF A VARIETY OF LAMELLARIN COMPOUNDS AND ANALOGUES | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | TSNAX, TSN, PLIN5 | LMNA 410/4885CYP3A4 3877/4885CYP2D6 1940/4885 |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | IL1B, IL1A, TNF | LMNA 3134/4885CYP3A4 1567/4885CYP2D6 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.